⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726618 | 0.86 | — | — | |
| SCHEMBL24478868 | 0.84 | ALDH1A1 (0.56) | — | |
| SCHEMBL8146532 | 0.84 | ALDH1A1 (0.54) | — | |
| SCHEMBL467449 | 0.80 | — | — | |
| SCHEMBL11060991 | 0.79 | ALDH1A1 (0.61) | — | |
| SCHEMBL6584208 | 0.79 | — | — | |
| SCHEMBL7094868 | 0.79 | ALDH1A1 (0.67) | — | |
| SCHEMBL7093157 | 0.77 | ALDH1A1 (0.70) | — | |
| SCHEMBL270296 | 0.77 | — | — | |
| SCHEMBL919385 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275975-A1 | Methods of Treating Neuropathies | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | ATHIRA PHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119684295-A | Bicyclic compounds for treating diseases and uses thereof | 雅斯娜制药公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518865-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518864-A1 | METHODS OF TREATING NEUROPATHIES | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| CN-119300834-A | Methods of treating neuropathy | 雅斯娜制药公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7312220-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238736-A9 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | SIRCAR JAGADISH | 2007-10-11 | — | — | US | disclosed |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054920-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |